Prot # GS-US-342-0109: A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Experienced Subjects with Chronic HCV Infection

Project: Research project

Project Details

StatusFinished
Effective start/end date5/14/135/14/16

Funding

  • Quintiles, Inc. (GS-US-342-0109)
  • Gilead Sciences, Inc. (GS-US-342-0109)